Vir Biotechnology Inc (NASDAQ: VIR) kicked off on Tuesday, up 3.39% from the previous trading day, before settling in for the closing price of $5.61. Over the past 52 weeks, VIR has traded in a range of $4.95-$14.45.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 423.44% over the past five years. While this was happening, its average annual earnings per share was recorded 12.21%. With a float of $87.46 million, this company’s outstanding shares have now reached $136.96 million.
Let’s look at the performance matrix of the company that is accounted for 408 employees. In terms of profitability, gross margin is 86.84%, operating margin of -707.97%, and the pretax margin is -715.51%.
Vir Biotechnology Inc (VIR) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Vir Biotechnology Inc is 36.22%, while institutional ownership is 51.33%. The most recent insider transaction that took place on Apr 03 ’25, was worth 474,239. In this transaction Chief Executive Officer of this company sold 79,712 shares at a rate of $5.95, taking the stock ownership to the 769,505 shares. Before that another transaction happened on Apr 03 ’25, when Company’s Officer and Director proposed sale 79,712 for $5.95, making the entire transaction worth $474,239.
Vir Biotechnology Inc (VIR) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.83 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 12.21% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 10.12% during the next five years compared to -18.74% drop over the previous five years of trading.
Vir Biotechnology Inc (NASDAQ: VIR) Trading Performance Indicators
Take a look at Vir Biotechnology Inc’s (VIR) current performance indicators. Last quarter, stock had a quick ratio of 8.71. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.72.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.83, a number that is poised to hit -0.84 in the next quarter and is forecasted to reach -3.23 in one year’s time.
Technical Analysis of Vir Biotechnology Inc (VIR)
Vir Biotechnology Inc (NASDAQ: VIR) saw its 5-day average volume 0.85 million, a negative change from its year-to-date volume of 1.92 million. As of the previous 9 days, the stock’s Stochastic %D was 64.17%. Additionally, its Average True Range was 0.44.
During the past 100 days, Vir Biotechnology Inc’s (VIR) raw stochastic average was set at 8.95%, which indicates a significant decrease from 52.47% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 82.77% in the past 14 days, which was lower than the 99.36% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.34, while its 200-day Moving Average is $8.26. Nevertheless, the first resistance level for the watch stands at $5.91 in the near term. At $6.02, the stock is likely to face the second major resistance level. The third major resistance level sits at $6.20. If the price goes on to break the first support level at $5.62, it is likely to go to the next support level at $5.44. The third support level lies at $5.33 if the price breaches the second support level.
Vir Biotechnology Inc (NASDAQ: VIR) Key Stats
The company with the Market Capitalisation of 795.43 million has total of 137,143K Shares Outstanding. Its annual sales at the moment are 74,210 K in contrast with the sum of -521,960 K annual income. Company’s last quarter sales were recorded 12,370 K and last quarter income was -104,590 K.
